THIRD QUARTER 2026 (JUL-SEP)

• Net sales totaled 72.6 (70.6) MSEK. Organic growth was 0.8%, while growth amounted to 2.9% after FX effects.
• Order intake amounted to 73.1 (57.6) MSEK. Organic growth was 27.8%, while growth amounted to 26.8% after FX effects.
• Earnings before interest, tax, depreciation and amortization (EBITDA) decreased to -6.2 (7.7) MSEK, including -8.5 MSEK of one-off non-recurring accounting adjustments related to prior periods.
• Net income for the period amounted to -14.3 (-0.3) MSEK.
• Earnings per share (EPS) amounted to -0.51 (-0.01) SEK.
• Cash flow from operating activities improved to 1.2 (-10.8) MSEK.

NINE MONTHS 2026 (JAN-SEP)

• Net sales totaled 214.4 (188.3) MSEK. Organic growth was 17.2%, while growth amounted to 13.9% after FX effects.
• Order intake amounted to 210.7 (158.8) MSEK. Organic growth was 40.1%, while growth amounted to 32.6% after FX effects.
• The order book at the end of the period was 131.6 (97.4) MSEK. Organic growth was 31.8%, while growth amounted to 35.1% after FX effects.
• Earnings before interest, tax, depreciation and amortization (EBITDA) amounted to -9.1 (-19.6) MSEK. This includes -8.5 MSEK of one-off non-recurring accounting adjustments from Q3.
• Net income for the period was -31.6 (-45.3) MSEK.
• Earnings per share (EPS) amounted to -1.12 (-1.61) SEK.
• Cash flow from operating activities totaled 36.0 (-21.8) MSEK
  
  CEO Frans Venker comments: 
  The third quarter was characterized by continued very strong demand from our customers, both in the Medical Device Industry (MDI) and Healthcare Systems (HCS) business areas. We received significant order intake growth of 27 percent year-over-year to SEK 73 million (58), marginally affected by currency effects. The order book grew by 35 percent to SEK 132 million (97). As we approach the end of the year, our focus remains on delivery and execution to convert this into sales growth.
  
  Looking ahead, the efficiency measures we have taken over the past year, together with strong order intake, support achieving our short- to medium-term financial targets. Performance across regions and business areas fluctuates from quarter to quarter, but the underlying demand is there. The longer-term trends point upwards for both MDI and Healthcare Systems.
  
  Webcast presentation of the interim report 
  The Q3 Interim Report for the period of July - September 2026 will be presented by CEO Frans Venker and
  CFO Rick van Veen on November 10, 2026, at 10:00 CEST.
  
  The live broadcast is followed by a Q&A moderated by Carnegie’s analyst Maria Karlsson-Osipova. 
  For more information and to register, please visit https://access.dnbcarnegie.com/companies/1430/live
  The presentation will be held in English. Participants are advised to register at least a few minutes in advance.